Trevi revs up extended-release opioid cough program
To view this email as a web page, click here

Today's Rundown

Featured Story

Lung safety review delays FDA decision on United's Tyvaso DPI

The FDA has delivered another twist in United Therapeutics’ long-running effort to win approval for the dry powder version of pulmonary hypertension drug Tyvaso. After rejecting the drug last year, the FDA has delayed its decision on the resubmission to review data on the safety of an excipient.

read more

Top Stories

COPD Foundation links arms with Ena on antiviral nasal spray ahead of phase 2 trials in COVID-19, flu

The COPD Foundation has stepped up to support development of Ena Respiratory’s antiviral nasal spray for use in people with chronic lung diseases. Ena is preparing to run phase 2 studies to test the ability of the nasal spray to prevent COVID-19 and influenza.

read more

Trevi revs up extended-release opioid cough program, exiting phase 2 early and racing into next stage

Trevi Therapeutics has linked its oral, extended-release formulation of the opioid analgesic nalbuphine to reduced cough frequency in idiopathic pulmonary fibrosis patients, prompting it to wrap the phase 2 trial up early and push deeper into the clinic.

read more

Hovione allies with Zerion to boost oral drug bioavailability

Hovione has expanded its oral drug delivery toolkit. Working with Zerion Pharma, the company plans to commercialize technology for overcoming the common problem of low drug solubility.

read more

After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery tech

Last last year, Moderna lost a legal bid to invalidate two Arbutus Biopharma patents tied to the delivery of its COVID-19 vaccine. At the time, it wasn’t so much a question of whether Arbutus would sue the mRNA vaccine giant for infringement, but when. Now, the other shoe has dropped.

read more

Resources

Whitepaper: Tailored, Dedicated Support Expedites COVID-19 Vaccine Trial

Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference.

Research: How Buffer Prep Services Alleviate Sudden Spikes in Campaign Volume

Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific

Whitepaper: QC for ex vivo manipulated cell lines and tissues

A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants.

Webinar: Using Next Best to Elevate your Omnichannel Marketing Strategy

Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events